These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27306546)

  • 1. Optimal Design for Informative Protocols in Xenograft Tumor Growth Inhibition Experiments in Mice.
    Lestini G; Mentré F; Magni P
    AAPS J; 2016 Sep; 18(5):1233-1243. PubMed ID: 27306546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination.
    Terranova N; Germani M; Del Bene F; Magni P
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):471-82. PubMed ID: 23812004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Combination of phenylbutyrate and 5-Aza-2'deoxycytidine inhibits human Kasumi-1 xenograft tumor growth in nude mice].
    Hao CL; Lin D; Wang LH; Xing HY; Wang M; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2004 Nov; 25(11):658-61. PubMed ID: 15634569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weichang'an and 5-fluorouracil suppresses colorectal cancer in a mouse model.
    Tao L; Yang JK; Gu Y; Zhou X; Zhao AG; Zheng J; Zhu YJ
    World J Gastroenterol; 2015 Jan; 21(4):1125-39. PubMed ID: 25632185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis.
    Mollard S; Ciccolini J; Imbs DC; El Cheikh R; Barbolosi D; Benzekry S
    Oncotarget; 2017 Apr; 8(14):23087-23098. PubMed ID: 28416742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling tumor growth inhibition and toxicity outcome after administration of anticancer agents in xenograft mice: A Dynamic Energy Budget (DEB) approach.
    Terranova N; Tosca EM; Borella E; Pesenti E; Rocchetti M; Magni P
    J Theor Biol; 2018 Aug; 450():1-14. PubMed ID: 29680449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker- versus drug-driven tumor growth inhibition models: an equivalence analysis.
    Sardu ML; Poggesi I; De Nicolao G
    J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):611-26. PubMed ID: 26209955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic inhibition of melanoma xenografts by Brequinar sodium and Doxorubicin.
    Dorasamy MS; Ab A; Nellore K; Wong PF
    Biomed Pharmacother; 2019 Feb; 110():29-36. PubMed ID: 30458345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer efficacy and toxicokinetics of a novel paclitaxel-clofazimine nanoparticulate co-formulation.
    Koot D; Cromarty D
    Drug Deliv Transl Res; 2015 Jun; 5(3):257-67. PubMed ID: 25795051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors.
    Lu Z; Wientjes TS; Au JL
    Pharm Res; 2005 Jul; 22(7):1069-78. PubMed ID: 16028007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
    Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
    Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy.
    Wang G; Wang Z; Li C; Duan G; Wang K; Li Q; Tao T
    Biomed Pharmacother; 2018 Oct; 106():275-284. PubMed ID: 29966971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PKPD modeling of acquired resistance to anti-cancer drug treatment.
    Eigenmann MJ; Frances N; Lavé T; Walz AC
    J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):617-630. PubMed ID: 29090407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis.
    Yang X; Shen J; Gao Y; Feng Y; Guan Y; Zhang Z; Mankin H; Hornicek FJ; Duan Z
    Int J Cancer; 2015 Oct; 137(8):2029-39. PubMed ID: 25904021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
    Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
    Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of antitumor effect by intratumoral administration of bax gene in combination with anticancer drugs in gastric cancer.
    Kim R; Minami K; Nishimoto N; Toge T
    Int J Oncol; 2001 Feb; 18(2):363-7. PubMed ID: 11172605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
    Zheng X; Chang RL; Cui XX; Avila GE; Hebbar V; Garzotto M; Shih WJ; Lin Y; Lu SE; Rabson AB; Kong AN; Conney AH
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3444-51. PubMed ID: 16740769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
    Jorgensen TJ; Tian H; Joseph IB; Menon K; Frost D
    Cancer Chemother Pharmacol; 2007 May; 59(6):725-32. PubMed ID: 16967299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.